2seventy bio, Inc. (“2seventy”) is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. 2seventy is led by an accomplished team with significant expertise and experience in this field, from discovery through clinical development to regulatory approval of Abecma (idecabtagene vicleucel, or ide-cel), the first chimeric antigen receptor (“CAR T”) cell therapy approved by the U.S. Food and Drug Administration (“FDA”) for multiple myeloma. 2seventy is advancing multiple clinical programs, including DARIC33, for the treatment of pediatric patients with relapsed and refractory acute myeloid leukemia, and bbT369, for the treatment of patients with B-cell non-Hodgkins lymphoma as well as multiple preclinical programs, including bbT4015, an engineered CAR T cell therapy targeting MUC16.